menu

Loading...

CYCN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.400

Open

1.310

VWAP

1.33

Vol

81.60K

Mkt Cap

5.10M

Low

1.290

Amount

108.52K

EV/EBITDA(TTM)

--

Total Shares

3.93M

EV

731.17K

EV/OCF(TTM)

--

P/S(TTM)

1.35

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Show More

Events Timeline

(ET)

2026-02-17

07:20:00

Cyclerion Receives Positive FDA Feedback on CYC-126

2026-01-05 (ET)

2026-01-05

16:10:00

Cyclerion Announces Exclusive Collaboration with Medsteer

2025-12-22 (ET)

2025-12-22

16:50:00

Cycurion Files to Sell 4.97M Shares of Common Stock for Holders

2025-09-23 (ET)

2025-09-23

16:08:20

Cyclerion Signs Licensing Deal with MIT and Unveils Strategic Relaunch

2025-05-06 (ET)

2025-05-06

16:59:34

Cyclerion Therapeutics files to sell 500K shares of common stock for holders

2024-12-17 (ET)

2024-12-17

07:20:51

Cyclerion Therapeutics announces update on next stage of growth

News

Newsfilter

02-17Newsfilter

Cyclerion Receives Positive FDA Feedback, Advancing CYC-126 Study

Benzinga

AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%

Benzinga

Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results

Benzinga

AngioDynamics Surpasses Expectations with $79.4M Sales and Break-Even EPS

NASDAQ.COM

01-06NASDAQ.COM

Cyclerion (CYCN) Enters Exclusive Collaboration with Medsteer to Advance CYC-126 Clinical Trials

Benzinga

Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%

Valuation Metrics

The current forward P/E ratio for Cyclerion Therapeutics Inc (CYCN.O) is -0.04, compared to its 5-year average forward P/E of -0.65. For a more detailed relative valuation and DCF analysis to assess Cyclerion Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.65

Current PE

-0.04

Overvalued PE

0.18

Undervalued PE

-1.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.11

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.31

Undervalued EV/EBITDA

-0.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

8.63

Current PS

2.50

Overvalued PS

21.93

Undervalued PS

-4.67

Financials

AI Analysis

Annual

Quarterly

Whales Holding CYCN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cyclerion Therapeutics Inc (CYCN) stock price today?

The current price of CYCN is 1.3 USD — it has decreased -3.7

What is Cyclerion Therapeutics Inc (CYCN)'s business?

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

What is the price predicton of CYCN Stock?

Wall Street analysts forecast CYCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYCN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cyclerion Therapeutics Inc (CYCN)'s revenue for the last quarter?

Cyclerion Therapeutics Inc revenue for the last quarter amounts to 875.00K USD, increased 351.03

What is Cyclerion Therapeutics Inc (CYCN)'s earnings per share (EPS) for the last quarter?

Cyclerion Therapeutics Inc. EPS for the last quarter amounts to -0.30 USD, increased 3.45

How many employees does Cyclerion Therapeutics Inc (CYCN). have?

Cyclerion Therapeutics Inc (CYCN) has 1 emplpoyees as of March 03 2026.

What is Cyclerion Therapeutics Inc (CYCN) market cap?

Today CYCN has the market capitalization of 5.10M USD.